Efficacy and correlation with predictive markers of gefitinib in pretreated Chinese patients with advanced NSCLC.

被引：0
|
作者：
Zhang, XT [1 ]
Li, LY [1 ]
Chang, XY [1 ]
Mu, XL [1 ]
Wang, SL [1 ]
Wang, MZ [1 ]
Zhong, W [1 ]
Zhang, L [1 ]
机构：
[1] Beijing Union Med Coll Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：680S / 680S
页数：1
相关论文
共 50 条
  • [1] Efficacy and predictive marker of gefitinib in pretreated Chinese patients with advanced NSCLC
    Zhang, X
    Li, L
    Mu, X
    Wang, S
    Cui, Q
    Wang, M
    Zhong, W
    Zhang, L
    [J]. LUNG CANCER, 2005, 49 : S275 - S275
  • [2] Brigatinib in pretreated patients with ALK-positive advanced NSCLC.
    Descourt, Renaud
    Perol, Maurice
    Rousseau-Bussac, Gaelle
    Planchard, David
    Mennecier, Bertrand
    Wislez, Marie
    Cortot, Alexis B.
    Guisier, Florian
    Gervais, Radj
    Galland, Loick
    Schott, Roland
    Dansin, Eric
    Arrondeau, Jennifer
    Auliac, Jean-Bernard
    Chouaid, Christos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Efficacy of gefitinib combined with bevacizumab versus gefitinib in advanced EGFR L858R NSCLC.
    Zhao, Xinmin
    Wu, Xianghua
    Wang, Huijie
    Yu, Hui
    Sun, Si
    Feng, Yu
    Wang, Jialei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
    F Cappuzzo
    S Bartolini
    G L Ceresoli
    S Tamberi
    A Spreafico
    L Lombardo
    V Gregorc
    L Toschi
    C Calandri
    E Villa
    L Crinò
    [J]. British Journal of Cancer, 2004, 90 : 82 - 86
  • [5] Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
    Cappuzzo, F
    Bartolini, S
    Ceresoli, GL
    Tamberi, S
    Spreafico, A
    Lombardo, L
    Gregorc, V
    Toschi, L
    Calandri, C
    Villa, E
    Crinò, L
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 82 - 86
  • [6] AFATINIB IN PLATINUM- AND GEFITINIB OR ERLOTINIB-PRETREATED PATIENTS WITH NSCLC. A SINGLE INSTITUTION EXPERIENCE IN A COMPASSIONATE-USE-PROGRAM
    Heigener, David F.
    Hildebrandt, Simone
    Reinmuth, Niels
    Reck, Martin
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1173 - S1173
  • [7] Efficacy of immunotherapy in Chinese patients with KRASmutant advanced NSCLC
    Wang, Z.
    Han, X.
    Peng, L.
    Guo, J.
    Kong, L.
    Huang, Y.
    Tang, N.
    Zhang, J.
    Wang, M.
    He, X.
    Li, Z.
    Peng, Y.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1067 - S1067
  • [8] EGFR copy number and gefitinib efficacy in advanced NSCLC
    [J]. Nature Clinical Practice Oncology, 2005, 2 (7): : 328 - 328
  • [9] Gefitinib in the treatment of elderly patients with advanced NSCLC
    Bearz, A.
    Fratino, L.
    Spazzapan, S.
    Berretta, M.
    Simonelli, C.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI22 - XI22
  • [10] Umbrella study of anticancer agents in Chinese patients with NSCLC.
    Zhao, Xin
    Xiao, Liyun
    Yang, Yunpeng
    Xie, Guoyun
    Fang, Wenfeng
    Ma, Yuxiang
    Zhao, Hongyun
    Wu, Kui
    Zhang, Li
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345